221 related articles for article (PubMed ID: 16841040)
1. Pipeline cherrypicking deal yields lucrative return.
Ransom J
Nat Biotechnol; 2006 Jul; 24(7):729. PubMed ID: 16841040
[No Abstract] [Full Text] [Related]
2. Overcoming the challenges in the pharma/biotech industry.
Graul AI; Prous JR
Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
[TBL] [Abstract][Full Text] [Related]
3. Trendspotting: betting strong but playing safe.
Anderegg MH; Thayer JM; Williams KM
Nat Biotechnol; 2006 Jul; 24(7):741-3. PubMed ID: 16924774
[TBL] [Abstract][Full Text] [Related]
4. Patently absurd?
Garber K
Nat Biotechnol; 2006 Jul; 24(7):737-9. PubMed ID: 16841046
[No Abstract] [Full Text] [Related]
5. Patent threat in emerging economies shifts to biotech.
Jayaranam K
Nat Biotechnol; 2008 May; 26(5):481-3. PubMed ID: 18464760
[No Abstract] [Full Text] [Related]
6. More blockbusters on the way. Pharmaceutical spending and the impact of pipeline drugs.
Kaddis A
Mich Health Hosp; 2001; 37(5):20-3. PubMed ID: 11569284
[TBL] [Abstract][Full Text] [Related]
7. Deal-making trends in oncology.
Moore K; Walker J
Nat Rev Drug Discov; 2009 Aug; 8(8):604. PubMed ID: 19644466
[No Abstract] [Full Text] [Related]
8. No immediate pain relief for the pharmaceutical industry.
Ahlborn H; Henderson S; Davies N
Curr Opin Drug Discov Devel; 2005 May; 8(3):384-91. PubMed ID: 15892254
[TBL] [Abstract][Full Text] [Related]
9. Biotech boom.
Jayaraman KS
Nature; 2005 Jul; 436(7050):480-3. PubMed ID: 16049469
[No Abstract] [Full Text] [Related]
10. Unlocking the money-making potential of RNAi.
Howard K
Nat Biotechnol; 2003 Dec; 21(12):1441-6. PubMed ID: 14647324
[No Abstract] [Full Text] [Related]
11. Reinventing an industry.
Mandavilli A
Nature; 2007 Jan; 445(7124):138-9. PubMed ID: 17215817
[No Abstract] [Full Text] [Related]
12. Surviving the blockbuster syndrome.
Service RF
Science; 2004 Mar; 303(5665):1796-9. PubMed ID: 15031490
[No Abstract] [Full Text] [Related]
13. US, Brazil tangle over IP rights to drugs.
Fox JL
Nat Biotechnol; 2001 Aug; 19(8):698. PubMed ID: 11479544
[No Abstract] [Full Text] [Related]
14. Silent running: the race to the clinic.
Nature; 2006 Aug; 442(7103):614-5. PubMed ID: 16900171
[No Abstract] [Full Text] [Related]
15. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
Graul AI; Revel L; Rosa E; Cruces E
Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
[TBL] [Abstract][Full Text] [Related]
16. Biotech patents-business as usual?
Lawrence S
Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
[No Abstract] [Full Text] [Related]
17. Changing university roles in the century of biotechnology.
Meagher LR; Bolivar F
Nat Biotechnol; 1998 Jul; 16(7):598-9. PubMed ID: 9661170
[No Abstract] [Full Text] [Related]
18. Deal watch: Trends in platform technology deal-making.
Walker J; Jacob J
Nat Rev Drug Discov; 2009 Dec; 8(12):923. PubMed ID: 19949395
[No Abstract] [Full Text] [Related]
19. Designs that enrich lives.
Link A; Stark H
Arch Pharm (Weinheim); 2007 Oct; 340(10):509-10. PubMed ID: 17912676
[No Abstract] [Full Text] [Related]
20. Biotech battle royale. Two firms fight over billion-dollar drug.
Sherrid P
US News World Rep; 2000 Mar; 128(11):52. PubMed ID: 10848209
[No Abstract] [Full Text] [Related]
[Next] [New Search]
